Medical News

RSS

Aetna announced participation in New York State's managed long-term care program

Aetna Better Health of New York today announced its participation in New York State's managed long-term care (MLTC) program. Aetna Better Health of New York, an Aetna Medicaid company, will serve people eligible for the state program in three New York City boroughs—Manhattan, Brooklyn and Queens—as well as Nassau and Suffolk counties on Long Island.

30 Nov 2012

Article highlights Asian-American children’s variable vulnerability to obesity

Asian-American children have been at low risk for being overweight or obese compared to other racial and ethnic groups in the U.S., but that may be changing. Yet as rates of overweight and obesity rise, the risk appears to vary depending on the Asian country of origin, according to an article in Childhood Obesity, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

30 Nov 2012

New detection method can identify genetic switches associated with breast cancer

Physicians may now be better at detecting breast cancer than ever before, but much more work remains to ensure accurate diagnosis is possible and especially to assess future risk. That's why researchers from Germany have been working to develop a new test of gene action to predict cancer risk both at first diagnosis and into the future.

30 Nov 2012

Aduro completes enrollment in CRS-207 and GVAX pancreas cancer vaccine Phase 2 trial

Aduro BioTech, Inc. announces completion of enrollment in the Phase 2 clinical trial of the sequential administration of two cancer vaccines, Aduro's CRS-207 and GVAX Pancreas Cancer Vaccine, in patients with metastatic pancreatic cancer.

30 Nov 2012

UBE3B gene linked to brain development disorder in children

Researchers have defined the gene responsible for a rare developmental disorder in children. The team showed that rare variation in a gene involved in brain development causes the disorder. This is the first time that this gene, UBE3B, has been linked to a disease.

30 Nov 2012

CSL, PharmaJet partner for needle-free delivery of Afluria influenza vaccine

PharmaJet Inc. has entered into a collaboration with CSL Limited to enable Afluria influenza vaccine to be delivered with the PharmaJet Stratis needle-free jet injector, as soon as the 2013-2014 flu season.

30 Nov 2012

Michigan State University, DWCHA receive teaching health center grant from HRSA

The Detroit Wayne County Health Authority (Health Authority) and Michigan State University College of Osteopathic Medicine (MSU) have been funded by the Health Resources and Services Administration (HRSA) to establish a teaching health center in Wayne County.

30 Nov 2012

FDA clears NeuroMetrix’s SENSUS Pain Management System

NeuroMetrix, Inc., a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, reported that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the disposable electrode that is used in conjunction with its SENSUS device.

30 Nov 2012

Correlation between childhood intelligence and chronic widespread pain in adulthood

A UK-based study team has determined that there is a correlation between childhood intelligence and chronic widespread pain (CWP) in adulthood, according to a new study published in the December issue of PAIN.

30 Nov 2012

Novel SIRT2 inhibitor protects against neuronal damage in animal models of Huntington's

Treatment with a novel agent that inhibits the activity of SIRT2, an enzyme that regulates many important cellular functions, reduced neurological damage, slowed the loss of motor function and extended survival in two animal models of Huntington's disease.

30 Nov 2012

Scientists define key underlying process implicated in multiple sclerosis

Scientists at the Gladstone Institutes have defined for the first time a key underlying process implicated in multiple sclerosis (MS)-a disease that causes progressive and irreversible damage to nerve cells in the brain and spinal cord. This discovery offers new hope for the millions who suffer from this debilitating disease for which there is no cure.

30 Nov 2012

Pivotal Therapeutics reports loss of $811,164 for third quarter 2012

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on cardiovascular disease and overall health today announced its financial results and operational highlights for the quarter ended September 30, 2012. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.

30 Nov 2012

Tips to prevent holiday headaches

Holidays are a time for family, friends, and happy memories. But those joyful moments can be associated with stress – from marathon shopping, preparing for celebrations, and traveling. Stress and other stimuli may trigger or increase your headaches.

30 Nov 2012

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat patients with genetically defined cancers, today announced the presentation of data evaluating the preclinical safety and efficacy of two of the Company's novel, potent and selective small molecule inhibitors. These inhibitors individually target DOT1L and EZH2, members of a class of epigenic enzymes called histone methyltransferases (HMTs).

30 Nov 2012

Modified vitamin D receptor may reduce risk of osteoporosis

Osteoporosis, or reduced bone mineral density that can increase the risk of fractures, may affect as many as 30% of women and 12% of men worldwide. One risk factor for osteoporosis is vitamin D deficiency.

30 Nov 2012

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).

30 Nov 2012

Varian's TrueBeam receives Indian AERB clearance for use in advanced radiosurgical treatments

Varian Medical Systems has received regulatory clearance from the Indian Atomic Energy Regulatory Board for the use of its unique TrueBeam High Intensity Mode for advanced radiosurgical treatments.

29 Nov 2012

Study: Only one third of MSM can easily access HIV services

A large-scale study of gay men and other men who have sex with men (MSM), conducted by the Global Forum on MSM & HIV (MSMGF), indicates that only one third of MSM can easily access condoms, lubricant, HIV testing, and HIV treatment.

29 Nov 2012

Alberta Children's Hospital performs first liver cell transplant in Calgary, Canada

A three-month-old Winnipeg girl has become the first patient in Canada to receive an experimental and potentially life-saving form of therapy to improve the function of her liver.

29 Nov 2012

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

Exelixis, Inc. today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for COMETRIQ (cabozantinib) for the proposed indication of treatment of progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).

29 Nov 2012

Medical News

Aetna announced participation in New York State's managed long-term care program

Article highlights Asian-American children’s variable vulnerability to obesity

New detection method can identify genetic switches associated with breast cancer

Aduro completes enrollment in CRS-207 and GVAX pancreas cancer vaccine Phase 2 trial

UBE3B gene linked to brain development disorder in children

CSL, PharmaJet partner for needle-free delivery of Afluria influenza vaccine

Michigan State University, DWCHA receive teaching health center grant from HRSA

FDA clears NeuroMetrix’s SENSUS Pain Management System

Correlation between childhood intelligence and chronic widespread pain in adulthood

Novel SIRT2 inhibitor protects against neuronal damage in animal models of Huntington's

Scientists define key underlying process implicated in multiple sclerosis

Pivotal Therapeutics reports loss of $811,164 for third quarter 2012

Tips to prevent holiday headaches

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Modified vitamin D receptor may reduce risk of osteoporosis

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Varian's TrueBeam receives Indian AERB clearance for use in advanced radiosurgical treatments

Study: Only one third of MSM can easily access HIV services

Alberta Children's Hospital performs first liver cell transplant in Calgary, Canada

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

Voltammetry and machine learning for real-time neurotransmitter detection

How real-time off-gas analysis improves fermentation process control

Advancing Drug Safety Assessment With AI, Predictive Modeling, and Human-Relevant Data

Latest News